GlassScriptPhysician profile
Michael L Alvares
NPI 1306055264
$11,453.47
in general payments reported to CMS, 2019-2025
36 companies · $2,209 in 2025
The $2,209 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,032 · 2020: $951 · 2021: $1,656 · 2022: $1,702 · 2023: $1,824 · 2024: $2,079 · 2025: $2,209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,011 · Education: $80.22 · Consulting Fee: $20.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,011.19 |
| Education | $80.22 |
| Consulting Fee | $20.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,023.66 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $1,402.58 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $920.67 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $868.58 | 2020-2025 | Cuvitru, Takhzyro, Eohilia |
| Novartis Pharmaceuticals Corporation | $800.55 | 2019-2025 | |
| Genzyme Corporation | $668.94 | 2021-2025 | |
| Covis Pharma Gmbh | $518.96 | 2019-2023 | |
| Grifols USA, LLC | $488.35 | 2021-2025 | Xembify, Gamunex-C |
| Amgen INC. | $350.69 | 2022-2025 | Tezspire |
| Csl Behring | $289.77 | 2019-2025 | Hizentra, Privigen |
| Genentech USA, INC. | $270.33 | 2019-2024 | Xolair |
| Optinose US, INC. | $259.57 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $203.34 | 2019-2022 | |
| Blueprint Medicines Corporation | $195.90 | 2023-2025 | Ayvakit |
| Boston Scientific Corporation | $144.06 | 2022-2023 | Wavewriter Alpha Prime 16 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $141.38 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $131.93 | 2021-2024 | Orladeyo |
| Kaleo, INC. | $120.62 | 2022-2023 | Auvi-Q |
| Octapharma USA, INC. | $101.81 | 2020-2023 | Cutaquig |
| Ars Pharmaceuticals Operations, INC. | $70.70 | 2025 | Neffy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.87 | 2019-2022 | |
| Organon LLC | $62.12 | 2025 | Vtama |
| Azurity Pharmaceuticals, INC. | $53.05 | 2025 | Alvesco |
| Teva Pharmaceuticals USA, INC. | $44.42 | 2022-2023 | |
| Adma Biomanufacturing LLC | $37.26 | 2021-2024 | |
| Lilly USA, LLC | $29.44 | 2025 | Ebglyss |
| Hikma Pharmaceuticals USA | $24.90 | 2023 | Ryaltris |
| Greer Laboratories, INC. | $23.92 | 2024 | Palforzia |
| Merck Sharp & Dohme LLC | $21.02 | 2023 | |
| Amag Pharmaceuticals, INC. | $20.78 | 2021 | |
| Incyte Corporation | $20.17 | 2025 | Opzelura |
| Galderma Laboratories, L.P. | $19.75 | 2025 | Nemluvio |
| Hospira, INC. | $18.04 | 2024 | |
| Shire North American Group INC | $17.16 | 2019 | |
| Alk-Abello, INC | $12.64 | 2019 | |
| Aimmune Therapeutics, INC. | $12.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Alvares listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.